Bloomberg Law
How Life Sciences Firms Can Reduce DOJ Enforcement Risks
May 6, 2021
The Anti-Kickback Statute has long been a driver of enforcement actions against the life sciences industry. In this article, Sidley lawyers explore areas that are most likely to draw enforcement scrutiny and how compliance programs can be updated to control risk going forward.
Contacts
Related Blogs
Capabilities
Suggested News & Insights
Texas Qui Tam Under Fire: Texas Appellate Dissent Raises Major Constitutional DoubtsMay 4, 2026DOJ Announces FOCUS Initiative to Work with Data Miners Filing Qui TamsApril 30, 2026New Guidance on U.S. Procurement Raises Risk to Federal Contractors From Potentially Discriminatory PracticesApril 29, 2026Ninth Circuit Rejects $8.5M Award Of Attorneys’ Fees to FCA WhistleblowerApril 14, 2026DOJ Announces First FCA Settlement Resolving Title VII Discrimination AllegationsApril 13, 2026White House and DOJ Announce Sweeping New Anti-Fraud InitiativesApril 10, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory